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Abstract
Previously, we reported that Galactoxylomannan (GalXM) activates the extrinsic and intrinsic apoptotic pathways through an
interaction with the glycoreceptors on T cells. In this study we establish the role of the glycoreceptor CD45 in GalXM-induced T
cell apoptosis, using CD45+/+ and CD452/2 cell lines, derived from BW5147 murine T cell lymphoma. Our results show that
whereas CD45 expression is not required for GalXM association by the cells, it is essential for apoptosis induction. In CD45+/+
cells, CD45 triggering by GalXM reduces the activation of Lck, ZAP70 and Erk1/2. Conversely, in CD452/2 cells, Lck was
hyperphosphorylated and did not show any modulation after GalXM stimulation. On the whole, our findings provide evidence
that the negative regulation of Lck activation occurs via CD45 engagement. This appears to be related to the capacity of GalXM
to antagonize T cell activation and induce T cell death. Overall this mechanism may be responsible for the immune paralysis
that follows GalXM administration and could explain the powerful immunosuppression that accompanies cryptococcosis.
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Introduction
CD45 is a type 1 transmembrane molecule found on the surface
of all nucleated hematopoietic cells and their precursors, except for
mature erythrocytes and platelets. It is one of the most abundant
cell surface glycoproteins, comprising up to 10% of the cell surface
area. The cytoplasmic region shares a remarkable 95% homology
across all mammalian species analyzed. In contrast, the extracel-
lular domain manifests only 35% homology [1,2]. CD45 is
expressed in various isoforms ranging in molecular weight from
180–235 kDa that arise from cell type-specific alternative splicing
of variable exons (exons 4/A, 5/B, 6/C and 7) encoding sequences
at the NH2-terminal domain [3,4]. Expression of different CD45
isoforms is cell type specific, and depends on the state of activation
and differentiation of hematopoietic cells [3]. B lymphocytes
express the high molecular weight isoform of 220 kDa (also termed
B220), which includes all alternatively spliced CD45-exons
(CD45RABC). Immature CD4+ CD8+ thymocytes express mainly
low molecular weight CD45 isoforms, whereas mature CD4+ or
CD8+ thymocytes and peripheral CD4+ CD8+ T cells can express
multiple isoforms [5]. Expression of different CD45 isoforms also
changes during T cell activation and ‘‘naı¨ve’’ T cells switch from
high molecular weight (CD45RB) to low molecular weight CD45
(CD45RO) isoforms upon stimulation. CD45 isoform patterns can
also change in response to cytokine [6]. Differential expression of
CD45 splice variants has frequently been used to distinguish
between ‘‘naı¨ve’’ CD45RB and ‘‘memory’’ CD45RO T cells.
However, this phenotypic distinction parallels the state of
activation of a given T cell: the CD45RO memory phenotype is
reversible because CD45RO cells can re-express high molecular
weight CD45 isoforms [7]. Moreover, the expression patterns for a
given population are not absolute and a single cell type can express
multiple CD45 isoforms [2]. CD45 has an intrinsic tyrosine
phosphatase activity and has been implicated in cell proliferation,
signaling and differentiation and is associated with the B cell
receptor during signaling [8].
Galactoxylomannan (GalXM), is a minor component of
capsular material of Cryptococcus neoformans (C. neoformans) which is
an ubiquitous encapsulated yeast that causes disease predomi-
nantly in immunocompromised hosts [9]. GalXM has an a-(1–6)
galactan backbone containing four potential short oligosaccharide
branch structures. The branches are 3-O-linked to the backbone
and consist of an a-Man-(1–3)-a-Man-(1–4)-b-Gal trisaccharide
with variable amounts of b-(1–2) or b-(1–3) xylose side groups
[10,11]. A recent study has also confirmed the presence of
glucuronic acid in the side chain [12]. GalXM has been shown to
induce TNF-a production from peripheral blood mononuclear cell
(PBMC) [13] and different cytokine profiles in RAW 264.7
macrophages [14].
De Jesus et al. recently investigated the immunological and
biological effects of GalXM in mice and reported that GalXM
immunization elicits a state of immunological paralysis in mice
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characterized by the disappearance of Ab-producing cells in spleen
[15]. In a previous paper we demonstrated that GalXM affected
selected immune responses, including a significant impairment of
T cell proliferation, an increase in IFN-c and IL-10 production,
Fas and FasL upregulation and induction of apoptosis of T
lymphocytes [16]. Moreover, in a recent study we demonstrated
that GalXM promoted apoptosis of T and Jurkat cells by
interacting with the glycoreceptors such as CD7, CD43 and
CD45. In particular we showed that GalXM-induced apoptosis
was primarily mediated by CD45 crosslinking. This observation
implies that a microbial compound can directly affect T cell
function by bypassing processing by antigen presenting cells (APC)
[17].
To investigate the requirement of CD45 expression in T cell
responses influenced by GalXM, we used CD45+/+ and CD452/2
cell lines derived from BW5147 murine T cell lymphoma [18] and
found that CD45 expression was required for the modulation of T
cell death and proliferation induced by GalXM.
Materials and Methods
Reagents and Media
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4 mM L-
glutamine was obtained from American Type Culture Collection
(ATCC) (Manassas, VA). Fetal calf serum (FCS) was purchased
from Gibco BRL (Paisley, Scotland). Penicillin-streptomycin
solution was obtained from Sigma-Aldrich (St. Louis, MO). R-
phycoerythrin (RPE)-conjugated mouse monoclonal antibody
(mAb) to CD45 (Rat IgG1k isotype) was obtained from
ImmunoTools GmbH (Friesoythe, Germany). 5-DTAF [5-(4,6-
Dicholotriazinyl) aminofluorescein] (5-DTAF) was purchased from
Chem Progress s.r.l. (Sesto Ulteriano, MI, Italy). Purified mAb to
CD3 (Hamster IgG1k isotype) was obtained from ImmunoTools.
Rabbit polyclonal antibodies to phospho-Lck (Tyr505) and Lck
were obtained from Cell Signaling Technology (Beverly, MA).
Rabbit polyclonal antibodies to phospho-Erk1/2 (Thr202), Erk1/
2 (C-16), phospho-ZAP70 (Tyr 493) and actin (H-300) were
obtained from Santa Cruz Biotechnology (Delaware Avenue, CA).
CD45 tyrosine phosphatase inhibitor BN82002 hydrochloride salt
(BN82002) was obtained from Sigma-Aldrich. The Csk inhibitor
(ASN 05260638) was obtained from Asinex (Moscow, Russia). Cy3
labelled conjugated affinity purified secondary antibody was
obtained from Chemicon Int. (Temecula, CA). Phytohemagglu-
tinin (PHA) and isotype controls were obtained from Sigma-
Aldrich. All reagent and medium were negative for endotoxin, as
assessed by Limulus amebocyte lysate assay (QCL-1000, BioWhit-
taker).
Cryptococcal polysaccharide
GalXM from C. neoformans was purified as described elsewhere
[19]. To eliminate LPS contamination in the GalXM preparation,
lyophilized GalXM was reconstituted in 1 X phosphate buffer
saline (PBS) and dialyzed in Endosafe LPS-free water for 3 weeks
until the dialysate resulted negative using Limulus amebocyte assay,
as previously described [15]. GalXM was checked again for LPS
contamination after reconstitution and resulted negative at the
threshold of the assay (,0.50 EU/ml).
Preparation of fluorescein-labelled GalXM (GalXM-FLUOS)
A fluorescein derivative of GalXM (GalXM-FLUOS) was
prepared by incubating GalXM with 5-DTAF according to study
done by De Belder A.N. et al. [20]. The GalXM-FLUOS was
separated from free 5-DTAF by ethanol precipitation and was
solubilised in PBS.
Cell lines
Murine T cell lymphoma cell line BW5147 (CD45+/+) and the
mutant cell line BW5147 (T2002) (CD452/2), derived from
BW5147 cells, were purchased from ATCC. Both types of
BW5147 cells used in this study are TCR positive [21]. More
specifically, these cells express some CD3 subunits, such as e, c
and small amounts of d, but lack a CD3 f chain, thus preventing
their TCR a and b chains from reaching the cell surface.
Nevertheless, upon CD3 stimulation these cell lines readily
respond to mAb to CD3 triggering, since there is a small amount
of CD3 e-c heterodimers that reach the surface and signal via their
ITAMs [22,23]. Cells were maintained in DMEM supplemented
with 10% FCS (complete medium) and antibiotics (100 U/ml
penicillin and 100 mg/ml streptomycin) at 37uC and 5% CO2.
Flow cytometry analysis
BW5147 and BW5147 (T2002) cells (both 16106/ml) were
incubated for 30 min or 2 h in the presence or absence of GalXM-
FLUOS (10 mg/ml) in complete medium at 37uC and 5% CO2. In
selected experiments, cells (both 16106/ml) were pre-treated for
5 min in the presence or absence of GalXM (10 mg/ml) and
subsequently incubated for 5 min in the presence or absence of
GalXM-FLUOS (10 mg/ml) as previously described. After incu-
bation, cells were washed twice, fixed with 4% formalin for 10 min
at room temperature (RT), washed and resuspended in 0.5 ml of
fluorescence buffer (FB) and analyzed by flow cytometry using
FACScan flow cytofluorometer (BD Biosciences). Results shown
are from one representative experiment of five independent
experiments with similar results. BW5147 and BW5147 (T2002)
cells (both 16106/ml) were incubated for 30 min, 2 or 18 h in the
presence or absence of GalXM (10 mg/ml) in complete medium at
37uC and 5% CO2. In selected experiments, cells (both 1610
6/ml)
were incubated for 30 min in the presence or absence of GalXM-
FLUOS (10 mg/ml) as previously described. After incubation, cells
were washed, fixed with 4% formalin for 10 min at RT, washed
and reacted with RPE-labelled mAb to CD45 (2 ml/tube) for
40 min on ice. After incubation, cells were washed twice with FB,
resuspended in 0.5 ml of FB and analyzed by flow cytometry. Data
are expressed as mean of fluorescence intensity (MFI) of labelled
cells and shown as FACScan histrograms or analyzed by two-color
flow cytometry and the results shown are from one representative
experiment of five independent experiments with similar results.
To evaluate phospho-ZAP70 activation, cells (both 16106/ml)
were pre-activated in the presence or absence of PHA (10 mg/ml)
for 30 min in complete medium at 37uC and 5% CO2 and then
incubated for 30 min in the presence or absence of GalXM
(10 mg/ml) or BN82002 (6 mM) [24,25] as previously described.
After incubation, cells were washed, fixed with 1.5% formalin for
10 min at RT, washed, incubated with absolute methanol (500 ml/
106 cells) for 10 min on ice to permeable cells, washed twice with
FB and incubated with rabbit polyclonal Ab to phospho-ZAP70
(dilution 1:50, Santa Cruz Biotechnology Inc.) followed by Cy3
labelled conjugated affinity purified secondary antibody (dilution
1:100, Chemicon Int.) [26]. Data are expressed as MFI of labelled
cells. Autofluorescence was assessed using untreated cells. Control
staining of cells with irrelevant antibody was used to obtain
background fluorescence values.
Fluorescence microscopy
BW5147 and BW5147 (T2002) cells (both 16106/ml) were
incubated for 30 min in the presence or absence of GalXM-
FLUOS (10 mg/ml) in complete medium at 37uC and 5% CO2.
After incubation, cells were washed and counterstained with
Evans’ Blue (StemCell Technologies Inc., Milan, Italy), and
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subsequently examined under fluorescent light microscopy (Carl
Zeiss, Jena, Germany). To study the association of GalXM to
CD45, cells (16106/ml) were incubated for 30 min or 2 h in the
presence of GalXM-FLUOS or, in selected experiments, in the
presence or absence of GalXM (10 mg/ml) in complete medium
at 37uC and 5% CO2. After incubation, cells were washed, fixed
with absolute methanol (1 ml/tube) for 10 min at RT and then
labelled with RPE mAb to CD45 for 40 min at 4uC. After
staining, cells were washed twice with FB, resuspended in FB,
collected by cytospin (26105/200 ml) at 700 g for 7 min, reacted
with 496-diamidino-2-phenylindole (DAPI, Sigma) and subse-
quently examined under fluorescent light microscopy (Carl
Zeiss). Irrelevant antibodies were used to obtain background of
fluorescence. Each condition was studied in triplicate, and three
images were taken for each sample. The figures shown are
representative.
Evaluation of apoptosis
BW5147 and BW5147 (T2002) cells (both 16106/ml) were
incubated for 18 h in the presence or absence of PHA (10 mg/ml),
mAb to CD3 (1 mg/ml) or GalXM (10 mg/ml) in complete
medium at 37uC and 5% CO2. In selected experiments, cells (both
16106/ml) were cultured in the presence or absence of Csk
inhibitor (ASN 05260638) [27] in complete medium for 10 min at
37uC plus 5% CO2. After incubation, cells were incubated for
18 h in the presence or absence of GalXM (10 mg/ml) in complete
medium at 37uC and 5% CO2. After stimulation, cells were
centrifuged, resuspended in hypotonic propidium iodide (PI)
Figure 1. GalXM association by BW5147 cells. (A) BW5147 and BW5147 (T2002) cells (both 16106/ml) were incubated for 30 min or 2 h in the
presence or absence of GalXM-FLUOS (10 mg/ml). After incubation, cells were analyzed by FACScan flow cytometry. Fluorescence histograms of
positive cells, from one representative experiment out of five with similar results, were reported. (B) In selected experiments, cells were incubated for
30 min as described above and subsequently examined under fluorescent light microscopy. Evans’ Blue was used as a counterstain. Note the green
fluorescence of GalXM-treated cells.
doi:10.1371/journal.pone.0012720.g001
Figure 2. CD45 expression on BW5147 cells treated with GalXM and GalXM colocalization with CD45. BW5147 and BW5147 (T2002)
cells (both 16106/ml) were incubated for 30 min, 2 h or 18 h in the presence or absence of GalXM (10 mg/ml). After incubation, cells were labelled
with RPE mAb to CD45 and analyzed by FACScan flow cytometry. The mean of fluorescence intensity (MFI) of labelled cells is shown as a histogram
(A) or is shown as FACScan histograms (B). Error bars denote s.e.m. *, p,0.05 (GalXM-treated vs untreated, n = 7). In selected experiments, cells
(16106/ml) were incubated for 30 min in the presence or absence of GalXM-FLUOS (10 mg/ml). After incubation, cells were labelled with RPE mAb to
CD45 and analyzed by FACScan flow cytometry. Dot plots of the percentage of double positive cells, from one representative experiment out of five
with similar results, were reported (C). Cells (16106/ml) were incubated for 30 min with GalXM-FLUOS (10 mg/ml) (green), labelled with RPE mAb to
CD45 (red), stained with DAPI (blue) and subsequently examined under fluorescent light microscopy (D).
doi:10.1371/journal.pone.0012720.g002
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solution (50 mg/ml) (Sigma-Aldrich), and kept for 1 h at RT. The
percentage of cells undergoing apoptosis was evaluated by flow
cytometry analysis as previously described [28]. Data are
expressed as fold increase in the percentage of apoptotic cells
and/or shown as FACScan histograms. In selected experiments,
BW5147 and BW5147 (T2002) cells (both 16106/ml) were
incubated as described above. After incubation, cells (26105/
200 ml) were collected by cytospin (700 g for 7 min) and stained by
Hemacolor.
Western blot analysis
BW5147 and BW5147 (T2002) cells (both 56106/ml) were
pre-treated for 30 min in the presence or absence of mAb to
CD3 (1 mg/ml) in complete medium at 37uC and 5% CO2.
After incubation, cells were washed with DMEM, resuspended
in complete medium and stimulated for 10 or 30 min in the
presence or absence of GalXM (10 mg/ml) or BN82002 (6 mM)
at 37uC and 5% CO2. After incubation, cells were washed and
lysed with mammalian protein extraction reagent in the
presence of protease and phophatase inhibitors (all from Pierce,
Rockford, IL). Protein concentration were determined with a
BCA protein Assay Reagent kit (Pierce). The lysates (30 mg of
each sample) were separated by sodium dodecyl-sulfate-10%
PAGE, transferred to a nitrocellulose membrane (Pierce) for 1 h
at 100 V in a blotting system (Bio-Rad, Hercules, CA) for
Western blot analysis, and the membranes were incubated
overnight with rabbit polyclonal Abs to phospho-Lck (dilution
1/1000; Cell Signaling Technology) and phospho-Erk1/2
(dilution 1/200; Santa Cruz Biotechnology Inc) in blocking
buffer. Detection was achieved with the appropriate secondary
Abs coupled to HRP, followed by Chemilucent Trial Kit
(Chemicon Int., Temecula, CA). Immunoblotting with rabbit
polyclonal Abs to Lck (dilution 1/1000; Cell Signaling
Technology) and Erk1/2 (dilution 1/200; Santa Cruz Biotech-
nology Inc.) were used as internal loading controls to ensure
equivalent amounts of protein in each lane. Immunoreactive
bands were visualized and quantified by Chemidoc Instrument
(Bio-Rad).
Figure 3. Segregation of CD45 GalXM-induced on BW5147 cells. Fluorescence microscopy analysis of BW5147 and BW5147 (T2002) cells
incubated for 2 h in the presence or absence (NS) of GalXM (A) or GalXM-FLUOS (green) (B) (both 10 mg/ml). After incubation, cells were labelled with
RPE mAb to CD45 (red) and then examined under fluorescent light microscopy in the presence of DAPI (blue). Note the CD45 segregation in BW5147
cells treated with GalXM (A). The colocalization of GalXM with CD45 and the receptor segregation on BW5147 cells was demonstrated in the merged
image of panel B (B). Original magnification 100x.
doi:10.1371/journal.pone.0012720.g003
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Figure 4. GalXM-induced apoptosis of BW5147 cells. (A) BW5147 and BW5147 (T2002) cells (both 16106/ml) were incubated for 18 h in the
presence or absence (NS) of PHA (10 mg/ml) or GalXM (10 mg/ml). After incubation, cells were collected by cytospin and stained by Hemacolor.
GalXM-treated cells exhibited altered morphology, surface blubs and nuclear fragmentation (arrows). N = cell nucleus; original magnification 40x. In
selected experiments, cells were incubated for 18 h in the presence or absence (NS) of PHA (10 mg/ml), mAb to CD3 (1 mg/ml) or GalXM (10 mg/ml).
CD45 Regulation by GalXM
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Evaluation of proliferation
BW5147 and BW5147 (T2002) cells (both 16106/ml) were pre-
treated for 30 min in the presence or absence of PHA (10 mg/ml)
in complete medium at 37uC and 5% CO2. After incubation, cells
were washed with DMEM, resuspended in complete medium and
stimulated for 48 h in the presence or absence of GalXM (10 mg/
ml) or BN82002 (6 mM) at 37uC and 5% CO2. After incubation,
cell proliferation was evaluated by the use of an ATP
bioluminescence kit (Via Light kit, Lonza Rockland Inc., ME).
Briefly, 100 ml of each sample was added to a 96-well culture plate,
50 ml of lysis reagent was added to each well, and after 10 min of
incubation, 100 ml of ATP monitoring reagent (AMR Plus) were
added to each sample. After 2 min of incubation at RT,
luminescence was measured by a luminometer (Infinite 200,
Tecan).
Statistical analysis
Data are reported as the mean 6 s.e.m. from duplicate samples
of 5–7 experiments and were evaluated by ANOVA. Post hoc
comparisons were done with Bonferroni’s test. A value of p,0.05
was considered significant.
Results
In a previous study, we showed that GalXM activates the
extrinsic and intrinsic apoptotic pathways through the interaction
with T cell glycoreceptors. In particular, CD45 was primarily
involved in Jurkat cells apoptosis while CD7 and CD43 mediated
human T cell apoptosis [17]. In the present study, we investigated
the effects of GalXM on CD45 requirement in T cell response. To
this end, we used BW5147 (CD45+/+) and BW5147 (T2002)
(CD452/2) cell lines derived from BW5147 murine T cell
lymphoma [18] routinely used for the study of the role of CD45
receptor in T cell response. Firstly, to verify the association of
GalXM to both cell lines, BW5147 and BW5147 (T2002) cells
were treated with GalXM-FLUOS. Results showed that GalXM
association was observed in both cell lines after 30 min and 2 h of
incubation (Fig. 1A). This result was confirmed by fluorescence
microscopic analysis. Indeed, both cell types showed similar rate of
GalXM association as observed in Figure 1B. The treatment of
BW5147 and BW5147 (T2002) cells with native unlabelled
GalXM significantly inhibited GalXM-FLUOS association (not
shown). To analyze whether in these cells GalXM binds to CD45,
we determined CD45 expression after GalXM addition. The
results showed that treatment with GalXM for 30 min masked
CD45 expression by 15% on BW5147 and this effect was still
evident after 2 h of incubation, but was lost after 18 h (Fig. 2A).
This effect was also shown with fluorescence histograms (Fig. 2B).
BW5147 (T2002) cells were used as a negative control (Fig. 2B). In
the analysis of CD45+/GalXM+ BW5147 cells we detected a
significant increase in the percentage of double positive BW5147
but not BW5147 (T2002) cells after 30 min of GalXM-FLUOS
treatment (Fig. 2C). The association of GalXM to CD45 was also
demonstrated by data reported in Figure 2D. In BW5147 cells,
GalXM colocalized with CD45 after 30 min of treatment. The
overlap of the green light from GalXM-FLUOS and the red light
from RPE-conjugated mAb to CD45 resulted in a yellow hue
(Fig. 2D). Moreover, colocalization of GalXM with CD45 resulted
in a subsequent segregation of CD45 to membrane patches after
2 h of incubation (Fig. 3A and B). BW5147 (T2002) was used as a
negative control (Fig. 2D and Fig. 3). Previously, we demonstrated
that GalXM was able to induce both the extrinsic and intrinsic
apoptotic pathways in T cells through the interaction with the
glycoreceptors, in particular through the interaction with CD45.
To analyze the precise role of CD45 in GalXM-mediated
apoptosis, BW5147 and BW5147 (T2002) cells were treated for
18 h with GalXM and apoptosis was evaluated. GalXM-treated
BW5147 cells exhibited apoptotic cellular changes consisting of an
altered morphology, characterized by surface blubs and nuclear
fragmentation (Fig. 4A). Conversely, BW5147 (T2002) cells did
not show any cellular changes in response to GalXM treatment
(Fig. 4A). Moreover, a significant increase in the percentage of
BW5147 apoptotic cells was evident 18 h after GalXM treatment,
while this effect was absent in BW5147 (T2002) cells. This effect
was also evident in cells activated with mAb to CD3 (Fig. 4B and
4C). PHA and mAb to CD3 were used as pro-apoptotic stimuli.
Ligation of the T cell receptor (TCR) with the peptide antigen
associated to major histocompatibility complex (MHC) molecules
initiates a signal transduction cascade that ultimately leads to T
cell activation [29]. Indeed, CD45 is a positive regulator of the
TCR signaling and it is essential for signal transduction after an
antigenic stimulation [29,30]. The first event is activation of the
Src family protein tyrosine kinases (SFKs) Fyn and Lck through
the dephosphorylation of their crucial tyrosine residues mediated
by CD45 [31,32]. To understand whether GalXM influences
TCR activation through its interaction with CD45, BW5147 cells
were activated for 30 min with mAb to CD3 and then incubated
for 10 or 30 min with GalXM. Our results showed that BW5147
cells stimulated with mAb to CD3 and then treated with GalXM
exhibited an augmented expression of phosphorylated inactive
form of Lck relative to cells only stimulated with mAb to CD3
(Fig. 5); conversely, BW5147 (T2002) cells showed a constitutive
hyperphosphorylation of Lck [31] that was unaffected by the
GalXM treatment (Fig. 5).
Lck activation leads to ZAP70 phosphorylation [31]. ZAP70 is a
member of the Syk family kinase predominantly involved in TCR
signaling initiation and subsequent T cell activation [33], therefore
we analyzed the effect of GalXM treatment on ZAP70 activation.
The results showed a decrease in the mean fluorescence intensity
(MFI) of phospho-ZAP70 in BW5147 cells pre-activated with PHA
and treated with GalXM, compared to cells treated only with
PHA (Fig. 6A). The GalXM treatment did not reduce the up-
regulation of phospho-ZAP70 in activated BW5147(T2002) cells
(Fig. 6A).
Given that signaling molecules such as Lck and the mitogen-
activated protein kinases (MAPKs) cooperate to produce TCR
activation signaling [29], a possible involvement of Erk1/2
activation in our experimental system was investigated. A decrease
of phosphorylated active form of Erk1/2 was observed in pre-
activated BW5147 cells treated with GalXM, compared to
GalXM untreated cells (Fig. 6B). No modulation of Erk1/2
phosphorylation was observed in BW5147 (T2002) cells treated or
untreated with GalXM (Fig. 6B).
A CD45-phosphatase activity inhibitor, BN82002, was used as a
control to mimic the inhibitory effect of GalXM on CD45 activity.
The results showed that in pre-activated BW5147 cells, BN82002
reduced phospho-ZAP70 and phospho-Erk1/2 activation. Phos-
pho-ZAP70 expression and phospho-Erk1/2 activation were not
After incubation, the percentage of cells undergoing apoptosis was evaluated by PI staining and analyzed using FACScan flow cytometry. Data are
expressed as fold increase of percentage of apoptotic cells (B), or shown as FACScan histograms from one representative experiment out of seven
with similar results (C). *, p,0.05 (treated vs untreated, n = 7). Error bars denote s.e.m.
doi:10.1371/journal.pone.0012720.g004
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modulated by treatment with GalXM or BN82002 in BW5147
(T2002) cells (Fig. 6A and 6B).
Finally we analyzed the biological effects of GalXM on BW5147
cell proliferation using BN82002 as a control. The augmented
proliferation in cells pre-activated with PHA was inhibited by the
treatment with GalXM or BN82002 (Fig. 6C). Again, this effect was
not observed in BW5147 (T2002) cells (Fig. 6C). Furthermore, we
sought to determine if GalXM association to CD45 induced
apoptosis of BW5147 cells through the inhibition of its phosphatase
activity. Thus, we treated cells with the Csk inhibitor ASN 05260638,
to induce a state of dephosphorylation of Lck, and then the cells were
incubated for 18 h in the presence or absence of GalXM. Pre-
treatment of BW5147 cells with ASN 05260638 inhibited the
induction of apoptosis mediated by GalXM (Fig. 7A). BW5147
(T2002) cells were used as a control (Fig. 7A). The inhibition of CD45
phosphatase activity, induced by the association of GalXM to CD45,
resulted in widespread T cell damage through the downregulation of
Lck activity. A model of the proposed mechanisms of inhibitory
effects induced by GalXM through CD45 is proposed (Fig. 7B).
Discussion
We previously reported that GalXM induces apoptosis of T cells
by the induction of Fas and FasL up-regulation that leads to the
activation of extrinsic and intrinsic apoptotic pathways through
the cleavage and recruitment of caspase-8, Bid, caspase-9 and
effector caspases 3, 6 and 7. These effects are dependent on
glycoreceptor engagement by GalXM [17]. Furthermore, glycor-
eceptors have also been reported to be involved in the inhibition of
T cell proliferation [34,35]. In this study we demonstrate that: i)
Figure 5. Phospho-Lck activation on BW5147 cells treated with GalXM. BW5147 and BW5147 (T2002) cells (both 56106/ml) were pre-
activated for 30 min in the presence or absence (NS) of mAb to CD3 (1 mg/ml) and then incubated for 10 or 30 min in the presence or absence (NS) of
GalXM (10 mg/ml). After incubation, cell lysates were analyzed by Western blotting. Membranes were incubated with antibodies to phospho-Lck and
Lck. pLck was normalized against Lck. *, p,0.05 (mAb to CD3 plus GalXM treated vs untreated, n = 5). Error bars denote s.e.m.
doi:10.1371/journal.pone.0012720.g005
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GalXM interaction with T cells was independent of CD45
expression; ii) CD45 was identified as the primary molecular target
for GalXM-induced T cell modulatory effects; iii) immunoregu-
lation required the interaction of CD45 with protein tyrosine
kinases such as Lck and ZAP70; iv) GalXM/CD45 interaction
inhibited Erk1/2 phosphorylation, this effect being directly
involved in the inhibition of T cell activation; and v) GalXM/
CD45 interaction induced apoptosis through the inhibition of
CD45 phosphatase activity.
Furthermore, in this study we provide evidence of direct
association of GalXM with T cells. Even though the GalXM
regulation of biological function of T cells was clearly apparent, a
relatively low percentage of immune cells were found to be
associated with GalXM. A possible explanation includes the low
dose of GalXM used (10 mg/ml), steric hindrance of GalXM, or
both of these reasons. The GalXM-induced effects include
inhibition of T cell activation and induction of T cell death. We
previosly demonstrated that the apoptosis induced by GalXM is
mediated by upregulation of Fas/FasL expression on T cells [17].
In this study we identify the CD45 activation pathway involved in
apoptosis induction and in direct inhibition of T cell activation.
LPS could possibly contaminate GalXM, but there are at least
two reasons to exclude this: the first is the negative results obtained
using the Limulus test, the second is the inhibitory nature of
GalXM, which is in contradistinction to the effects of LPS. The
absence of measurable LPS combined with the GalXM-mediated
immunosuppressive effects essentially rules out the possibility that
LPS contributed to the observed results. The induction of T cell
apoptosis mediated by GalXM might be, in several aspects, similar
to that induced by galectins. Galectins are a family of
carbohydrate-associated mammalian proteins with an affinity for
b-galactosides that positively or negatively regulates apoptosis
[35,36,37]. Galectin-1 and galectin-3, the most ubiquitously
expressed members of the galectins family, are expressed in
several tissues including thymus and lymph nodes [36]. These two
lectins recognize discrete sets of oligosaccharide ligands. The
similarities between galectins and GalXM include a) regulation of
Fas-mediated death pathways and impairment of T cell activation;
b) association to T cells and induction of their death [38,39]; and
c) CD45 engagement and related biological effects.
Multiple isoforms of CD45 exist as a result of the alternative
RNA splicing [3,40], this mechanism implies concurrent changes
in glycosylation, for example activated T cells express CD45 that
are hyposialylated compared to resting T cells [41].
The fact that GalXM is able to induce apoptotic and
suppressive effects particularly in pre-activated T cells suggests
that GalXM could preferentially bind to hyposialylated, low
molecular weight CD45 isoforms (CD45RO). In turn this suggests
that CD45 glycosylation regulates the susceptibility to GalXM-
mediated T cell death. Furthermore, given that CD45 is also
expressed in B cells, the mechanisms of depletion of B cells and of
immunological paralysis recently described by De Jesus et al. [15]
could be related to the alteration of signaling cascade of BCR-
induced activation, caused by CD45 engagement by GalXM [42].
CD45 interaction with its ligand can induce dimerization [43].
The negative regulation of CD45, associated with inhibition of its
phosphatase activity, has been ascribed to CD45 dimerization.
Indeed, CD45RO homodimerizes more easily than high molec-
ular weight isoforms, leading to inhibition of phosphatase activity
[40]; this model reinforces the concept that GalXM interacts
particularly with CD45RO.
Cross-linking of CD45 has been implicated in apoptosis induction
[44,45] and a role for CD45RO has been suggested [46]. Given that
the major substrate of CD45 is Lck, one might posit that it is
implicated in the apoptotic pathway activation. There are studies
reporting that CD45 and Lck are not involved in Fas-induced
apoptosis, because Fas-induced apoptosis was similar in wild type
and cells deficient in CD45 or Lck [47,48]. However, it is
noteworthy that the cells used in some of those studies were not
completely deficient in CD45 [49], and therefore, these studies were
not conclusive. In a recent paper we demonstrated that GalXM
induces Fas/FasL expression on T cells and this phenomenon is
greatly responsible of apoptosis induction. Despite convincing
evidence for CD45 implication in apoptosis regulation, very little is
known about the mechanisms and pathways involved in this
process. A relationship between CD45 expression and apoptosis
activation was discussed in this paper. We demonstrated that
GalXM induced apoptosis of T cells through inhibition of CD45
phosphatase activity. However, we were able to observe an increase
of GalXM-induced phospho-Lck only in activated cells. Indeed,
phospho-Lck was tested after 10 and 30 min, while apoptosis
induction was evidenced after 18 h. Thus the kinetics and quantity
of phospho-Lck activation could be different in inactivated and
activated cells and, as a consequence, observable, at least at 10 and
30 min, only in activated cells. GalXM/CD45 interaction clusters
and segregates CD45 and it is possible that this segregation is
regulated by attachment to the cytoskeleton through the linker
protein fodrin [41]. An association also exists between DNA
fragmentation and Lck phosphorylation. Indeed, CD45 initiates T
cell antigen signal transduction by dephosphorylating Lck [50,51].
The hypothesis that Lck is implicated in induction of apoptosis is
supported by the constitutive hyperphosphorylation of Lck observed
in CD452/2 cells that are refractory to GalXM-induced apoptosis.
This in turn is supported by recent studies demonstrating that
the tyrosine kinase Lck is involved in the regulation of apoptosis,
particularly in the mitochondrial-induced pathway [52,53]. Given
that GalXM activation of this pathway was previously observed
[17], the results reported in this paper support this hypothesis and
suggest the possible implication of ZAP70 substrate.
The correlation between Lck phosphorylation and apoptosis
induction is supported by the fact that the induction of
dephosphorylation of Lck, results in inhibition of apoptosis
GalXM-induced. Moreover, a CD45-phosphatase activity inhib-
itor, that should mirror the GalXM signal pathway, inhibits T cell
Figure 6. Phospho-ZAP70, phospho-Erk activation and proliferation of BW5147 cells treated with GalXM or BN82002. (A) BW5147
and BW5147 (T2002) cells (both 16106/ml) were pre-activated for 30 min in the presence or absence (NS) of PHA (10 mg/ml) and then incubated for
30 min in the presence or absence (NS) of GalXM (10 mg/ml) or BN82002 (6 mM). After incubation cells were labelled with antibody to phospho-
ZAP70 and then analyzed by FACScan flow cytometry. The mean of fluorescence intensity (MFI) of labelled cells is shown as a histogram. *, p,0.05
(treated vs untreated, n = 7). (B) BW5147 and BW5147 (T2002) cells (both 56106/ml) were pre-activated for 30 min in the presence or absence (NS) of
mAb to CD3 (1 mg/ml) and then incubated for 30 min in the presence or absence (NS) of GalXM (10 mg/ml) or BN82002 (6 mM). After incubation, cell
lysates were analyzed by Western blotting; membranes were incubated with antibodies to phospho-Erk1/2 and Erk1/2. pErk was normalized against
Erk. *, p,0.05 (treated vs untreated, n = 7). Error bars denote s.e.m. (C) BW5147 and BW5147 (T2002) cells (both 16106/ml) were pre-activated for
30 min in the presence or absence (NS) of PHA (10 mg/ml) and then incubated for 48 h in the presence or absence (NS) of GalXM (10 mg/ml) or
BN82002 (6 mM). After incubation, cell proliferation was evaluated by ViaLight Plus Kit. *, p,0.05 (treated vs untreated, n = 7). Error bars denote s.e.m.
doi:10.1371/journal.pone.0012720.g006
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activation. Building on these results one could posit that GalXM
could damage T cells by inducing apoptosis as well as by inhibiting
other biological functions. More investigations need to be done to
clarify the relationship between these effects.
MAPK involvement in apoptosis has been demonstrated
[29,44]. Erk1/2 activation can protect cells from cisplatinum-
induced apoptosis [54], and Erk1/2 is also important in recruiting
cFos to the nucleus, where the activation of transcription factor
AP-1 regulates cell cycle and apoptosis [55]. In addition, Erk1/2
activation can occur via Lck [29].
The evidence for the involvement of MAPK in apoptosis is
contradictory and depends on the cell type and the type of
apoptosis inducer [29,44]. Here we report that Erk1/2 is down-
regulated by GalXM stimulation exclusively in CD45 wild type
cells, while hyperphosphorylation of Erk1/2 is observed in
CD452/2 cells. Thus, we hypothesize that Erk1/2 is implicated
in the induction of GalXM-mediated apoptosis.
Indeed, GalXM induces apoptosis as well as inhibition of T cell
activation. However, we cannot distinguish the involvement of the
signaling mechanism in these two processes. It has been reported
that CD45 is sequentially cleaved by serine/metalloproteinase and
c-secretase during its activation by fungal stimuli. CD45 cleavages
release a fragment of the CD45 cytoplasmic tail (ct-CD45). Soluble
ct-CD45 selectively binds to pre-activated T cells and inhibits T
cell proliferation [56]. Given that GalXM is a fungal antigen
[11,12] it might be that soluble ct-CD45 is released, in the
presence of GalXM, and this might contribute to the inhibition of
T cell activation.
With regards to cryptococcal pathogenesis our results detail the
powerful immunosuppressive action of GalXM through its effects
on CD45-related apoptosis. This mechanism may be responsible
for the widespread disruption of the immune function that follows
GalXM administration [13,14,15,16], and for the immunosup-
pression that accompanies cryptococcosis.
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Figure 7. Blocking of CD45 phosphotase activity induces apoptosis and inhibits proliferation of BW5147 cells treated with GalXM.
(A) BW5147 and BW5147 (T2002) cells (both 16106/ml) were pre-treated for 10 min with ASN 05260638 (20 mM) and then incubated for 18 h in the
presence or absence (NS) of GalXM (10 mg/ml). After incubation, the percentage of cells undergoing apoptosis was evaluated by PI staining and
analyzed using FACScan flow cytometry. Data are expressed as FACScan histograms from one representative experiment out of five with similar
results. (B) Schematic representation of GalXM effect on BW5147 cells. GalXM induces immunosuppressive effects on T cells through Lck inactivation.
This effects occurs after GalXM association to CD45, which inhibits its dephosphatase activity.
doi:10.1371/journal.pone.0012720.g007
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